Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

diluted, compared to a net income of $0.29 per share, basic, and $0.25 per share, diluted, for the same period in 2007. Net income per share for the year ended December 31, 2008 was $0.95 per share, basic, and $0.83 per share, diluted, compared to net income of $1.37 per share, basic, and $1.21 per share, diluted, for the same period in 2007.

The primary drivers of the decrease in net income for the fourth quarter and year ended December 31, 2008 were the increase in R&D, SG&A and intangible amortization expenses, and lower interest income offset by the lower tax expense. Additionally, in the fourth quarter of 2008 we had a $2.3 million charge to write down to fair value our previous corporate headquarters which is currently held for sale.

Operating Highlights

During the three months and year ended December 31, 2008, net sales increased 4.9 percent and 14.0 percent, respectively, compared to the same periods in 2007.

The cost of sales for the three months and year ended December 31, 2008 increased $0.1 million and remained consistent, respectively, as compared to the same periods in 2007. For the three months and year ended December 31, 2008 the cost of sales was $2.1 million and $8.9 million, respectively, compared to $2.0 million and $8.9, respectively, for the same period in 2007.

Investment in our product pipeline and the company continued to grow as research and development (R&D) and selling, general and administrative (SG&A) expenses in the fourth quarter and year ended December 31, 2008 were $43.6 million and $131.7 million, respectively compared to $25.2 million and $72.9 million for the fourth quarter and year ended December 31, 2007, respectively. The quarter increases were due primarily to our investments in our infrastructure related to our development programs, costs to support the Cinryze open label trial and launch related costs, an
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ... an optimized Erk inhibitor molecule for development, thus ... a new class of potential cancer therapies. ... target for therapeutic intervention in cancer. Recently approved ... for B-Raf and Mek inhibitors. Erk inhibitors may ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... PRC Clinical, a Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi ... patient recruitment services. The core expertise of PRC Clinical is focused on Clinical ...
(Date:7/29/2015)... ... July 29, 2015 , ... Costello served as Lead ... to protect the Orange County, Texas area from future storm surge flooding, such ... in determining several potential levee alignment alternatives for providing protection, Costello also balanced socio-economic ...
(Date:7/29/2015)... ... July 29, 2015 , ... Asymmetrex, ... good progress in evaluating the full range of capabilities of its unique cache ... stem cells perform the day-to-day renewal and repair of normal tissues and organs. ...
Breaking Biology Technology:Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Preventing Storm Surge Flooding in Houston 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4
... CARLSBAD, Calif., May 4 GenVault Corporation is delighted ... Sales and Marketing. With over 25 years of ... of driving sales growth in both the domestic and ... held the position of Vice President of Sales, Americas, ...
... Laboratories, Inc. announced today the launch of its ... Tablets by the U.S. Food and Drug Administration. ... Bottles of 100 and 500, 500mg Tablets Bottles ... for immediate shipment to wholesalers and pharmacies nationwide.(Photo: ...
... May 4 Circ Pharma Limited ("Circ Pharma") ... have entered into a,Development Agreement to develop a ... to moderately severe pain. , ... delivery,technology enabling once daily dosing. Circ,s technology provides ...
Cached Biology Technology:Shane Lyons Joins GenVault Corporation as Vice President of Sales and Marketing 2Shane Lyons Joins GenVault Corporation as Vice President of Sales and Marketing 3Roxane Laboratories, Inc. Announces the Launch of Mycophenolate Mofetil 250mg Capsules and 500mg Tablets 2Circ Pharma Limited Enters Into Development Agreement for Chrono Tramadol With Elan Corporation Plc 2
(Date:7/21/2015)... -- Today, ZTE announced its Android smartphone Axon, featuring ... revenues in 2015 that relate to sales of FPC1025 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... China and we are proud that ... Axon , its first ...
(Date:7/20/2015)...  Acuity Market Intelligence,s latest research "The Global ... and Privacy" forecasts that between 2014 and 2020 ... downloaded to smart mobile devices by 2.2 billion ... projected to generate more than $67.9 billion in ... period.    "Biometrics is at the ...
(Date:7/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the fourth quarter and ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-455-2260 ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... in BioMed Central,s open access journal BMC Genomics ... with its 50cm diameter flowers, has ,stolen, genes from its ... that their functions range from respiration to metabolism, and that ... activity. Vertical gene transfer is that between parents and ...
... toy ecosystem modeling and paleontological evidence as a crystal ... predict we,re on a much worse collision course with ... Approaching a state-shift in Earth,s biosphere, a paper just ... span a multitude of disciplines, suggest our planet,s ecosystems ...
... Working with researchers at the University of Pittsburgh ... Barbara have found high levels of beneficial omega-3 fatty ... woman as compared to women in the United States. ... journal Maternal and Child Nutrition . The ...
Cached Biology News:Parasitic plants 'steal' genes from their hosts 2Study predicts imminent irreversible planetary collapse 2UCSB anthropologists finds high levels of omega-3 fatty acids in breast milk of Amerindian women 2
8.1.1...
Human SCP3 Affinity Purified Polyclonal Ab Keywords: Spermatogenesis, meiosis Protein Family: Cell Cycle...
... and efficient purification of DNA and oligonucleotides ... by gravity flow.Prepacked with Sephadex G-25 DNA ... CG/ICP Biocide.Available in three sizes depending on ... ml (NAP-10) or 2.5 ml (NAP-25).Useful for ...
Homo sapiens alcohol dehydrogenase 5 (class III), chi polypeptide (ADH5), mRNA....
Biology Products: